Therapeutic approaches for corneal neovascularization
Open Access
- 10 December 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Eye and Vision
- Vol. 4 (1), 1-10
- https://doi.org/10.1186/s40662-017-0094-6
Abstract
Angiogenesis refers to new blood vessels that originate from pre-existing vascular structures. Corneal neovascularization which can lead to compromised visual acuity occurs in a wide variety of corneal pathologies. A large subset of measures has been advocated to prevent and/or treat corneal neovascularization with varying degrees of success. These approaches include topical corticosteroid administration, laser treatment, cautery, and fine needle diathermy. Since the imbalance between proangiogenic agents and antiangiogenic agents primarily mediate the process of corneal neovascularization, recent therapies are intended to disrupt the different steps in the synthesis and actions of proangiogenic factors. These approaches, however, are only partially effective and may lead to several side effects. The aim of this article is to review the most relevant treatments for corneal neovascularization available so far.Keywords
This publication has 118 references indexed in Scilit:
- Resistance to antivascular endothelial growth factor treatment in age-related macular degenerationDrug Design, Development and Therapy, 2013
- Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) Vs Bevacizumab (Avastin)The Ocular Surface, 2012
- Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic TherapiesGenes & Cancer, 2011
- Novel aspects of corneal angiogenic and lymphangiogenic privilegeProgress in Retinal and Eye Research, 2010
- Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growthNature Medicine, 2009
- Therapeutic antibodies: successes, limitations and hopes for the futureBritish Journal of Pharmacology, 2009
- Topical Bevacizumab in the Treatment of Corneal NeovascularizationAmerican Journal of Ophthalmology, 2009
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Corneal avascularity is due to soluble VEGF receptor-1Nature, 2006